| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A message from the New Editor-in-Chief
|
Giske, Christian G.
|
|
2010
|
21-22 |
1-2 |
p. 1-
1 p.
|
article
|
| 2 |
Antimicrobial resistance among Enterobacteriaceae in South America: History, current dissemination status and associated socioeconomic factors
|
Bonelli, Raquel Regina
|
|
2014
|
21-22 |
1-2 |
p. 24-36
13 p.
|
article
|
| 3 |
Cancer drug resistance: The central role of the karyotype
|
Duesberg, Peter
|
|
2007
|
21-22 |
1-2 |
p. 51-58
8 p.
|
article
|
| 4 |
Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy
|
Maddika, Subbareddy
|
|
2007
|
21-22 |
1-2 |
p. 13-29
17 p.
|
article
|
| 5 |
Cellular senescence and cancer chemotherapy resistance
|
Gordon, Ryan R.
|
|
2012
|
21-22 |
1-2 |
p. 123-131
9 p.
|
article
|
| 6 |
Collateral sensitivity as a strategy against cancer multidrug resistance
|
Pluchino, Kristen M.
|
|
2012
|
21-22 |
1-2 |
p. 98-105
8 p.
|
article
|
| 7 |
Contribution of tumoral and host solute carriers to clinical drug response
|
Sprowl, Jason A.
|
|
2012
|
21-22 |
1-2 |
p. 5-20
16 p.
|
article
|
| 8 |
Drug resistance in the mouse cancer clinic
|
Rottenberg, Sven
|
|
2012
|
21-22 |
1-2 |
p. 81-89
9 p.
|
article
|
| 9 |
Drug resistance: Still a daunting challenge to the successful treatment of AML
|
Shaffer, Brian C.
|
|
2012
|
21-22 |
1-2 |
p. 62-69
8 p.
|
article
|
| 10 |
Drug resistance updates: Top 10 most requested ScienceDirect full-text downloads in 2004
|
|
|
2005
|
21-22 |
1-2 |
p. 109-112
4 p.
|
article
|
| 11 |
Drugs and drug resistance in African trypanosomiasis
|
Delespaux, Vincent
|
|
2007
|
21-22 |
1-2 |
p. 30-50
21 p.
|
article
|
| 12 |
Editorial
|
Giske, Christian G.
|
|
2012
|
21-22 |
1-2 |
p. 1-
1 p.
|
article
|
| 13 |
Editorial Board
|
|
|
2009
|
21-22 |
1-2 |
p. i-
1 p.
|
article
|
| 14 |
Editorial Board
|
|
|
|
21-22 |
1-2 |
p. i
|
article
|
| 15 |
Editorial Board
|
|
|
2006
|
21-22 |
1-2 |
p. i-
1 p.
|
article
|
| 16 |
Editorial Board
|
|
|
2005
|
21-22 |
1-2 |
p. i-
1 p.
|
article
|
| 17 |
Editorial Board
|
|
|
2007
|
21-22 |
1-2 |
p. i-
1 p.
|
article
|
| 18 |
Editorial Board
|
|
|
2010
|
21-22 |
1-2 |
p. i-
1 p.
|
article
|
| 19 |
Editorial Board
|
|
|
2013
|
21-22 |
1-2 |
p. i-
1 p.
|
article
|
| 20 |
Editorial Board
|
|
|
2012
|
21-22 |
1-2 |
p. i-
1 p.
|
article
|
| 21 |
Editorial Board
|
|
|
2014
|
21-22 |
1-2 |
p. i-
1 p.
|
article
|
| 22 |
Eight years of Drug Resistance Updates
|
Georgopapadakou, Nafsika
|
|
2005
|
21-22 |
1-2 |
p. 1-2
2 p.
|
article
|
| 23 |
Endostatin: The logic of antiangiogenic therapy
|
Abdollahi, Amir
|
|
2005
|
21-22 |
1-2 |
p. 59-74
16 p.
|
article
|
| 24 |
Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
|
Wilting, Roel H.
|
|
2012
|
21-22 |
1-2 |
p. 21-38
18 p.
|
article
|
| 25 |
Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy
|
Abdollahi, Amir
|
|
2010
|
21-22 |
1-2 |
p. 16-28
13 p.
|
article
|
| 26 |
Extended-spectrum cephalosporin-resistant gram-negative organisms in livestock: An emerging problem for human health?
|
Seiffert, Salome N.
|
|
2013
|
21-22 |
1-2 |
p. 22-45
24 p.
|
article
|
| 27 |
Fas/CD95 death receptor and lipid rafts: New targets for apoptosis-directed cancer therapy
|
Mollinedo, Faustino
|
|
2006
|
21-22 |
1-2 |
p. 51-73
23 p.
|
article
|
| 28 |
Fibroblast activation protein-α and dipeptidyl peptidase IV (CD26): Cell-surface proteases that activate cell signaling and are potential targets for cancer therapy
|
Kelly, Thomas
|
|
2005
|
21-22 |
1-2 |
p. 51-58
8 p.
|
article
|
| 29 |
Immunotherapy: A useful strategy to help combat multidrug resistance
|
Curiel, Tyler J.
|
|
2012
|
21-22 |
1-2 |
p. 106-113
8 p.
|
article
|
| 30 |
Is there a serious risk of resistance development to azoles among fungi due to the widespread use and long-term application of azole antifungals in medicine?
|
Hof, Herbert
|
|
|
21-22 |
1-2 |
p. 25-31
|
article
|
| 31 |
Linezolid update: Stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms
|
Mendes, Rodrigo E.
|
|
2014
|
21-22 |
1-2 |
p. 1-12
12 p.
|
article
|
| 32 |
Literature highlights: Recent research in infectious disease drug resistance
|
|
|
2007
|
21-22 |
1-2 |
p. 68-75
8 p.
|
article
|
| 33 |
Literature highlights: recent research in infectious disease drug resistance
|
|
|
2005
|
21-22 |
1-2 |
p. 99-108
10 p.
|
article
|
| 34 |
Literature Highlights: Recent research in infectious disease drup resistance
|
|
|
2006
|
21-22 |
1-2 |
p. 87-100
14 p.
|
article
|
| 35 |
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use
|
Pérez-Victoria, F. Javier
|
|
2006
|
21-22 |
1-2 |
p. 26-39
14 p.
|
article
|
| 36 |
Mechanisms of resistance to FLT3 inhibitors
|
Chu, S. Haihua
|
|
2009
|
21-22 |
1-2 |
p. 8-16
9 p.
|
article
|
| 37 |
Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy
|
Efferth, Thomas
|
|
2005
|
21-22 |
1-2 |
p. 85-97
13 p.
|
article
|
| 38 |
Meetings Calendar
|
|
|
2009
|
21-22 |
1-2 |
p. 51-54
4 p.
|
article
|
| 39 |
Meetings Calendar
|
|
|
|
21-22 |
1-2 |
p. 61
|
article
|
| 40 |
Meetings Calendar
|
|
|
2007
|
21-22 |
1-2 |
p. 76-79
4 p.
|
article
|
| 41 |
Microtubule-targeting agents in angiogenesis: Where do we stand?
|
Pasquier, Eddy
|
|
2006
|
21-22 |
1-2 |
p. 74-86
13 p.
|
article
|
| 42 |
Modeling therapy resistance in genetically engineered mouse cancer models
|
Rottenberg, Sven
|
|
|
21-22 |
1-2 |
p. 51-60
|
article
|
| 43 |
Multiple paths to a drug resistance phenotype: Mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs
|
Fojo, Tito
|
|
2007
|
21-22 |
1-2 |
p. 59-67
9 p.
|
article
|
| 44 |
Mutational ‘hot-spots’ in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: Sequence and structural comparison
|
Volpato, Jordan P.
|
|
2009
|
21-22 |
1-2 |
p. 28-41
14 p.
|
article
|
| 45 |
Nanoways to overcome docetaxel resistance in prostate cancer
|
Ganju, Aditya
|
|
2014
|
21-22 |
1-2 |
p. 13-23
11 p.
|
article
|
| 46 |
New developments in Hsp90 inhibitors as anti-cancer therapeutics: Mechanisms, clinical perspective and more potential
|
Li, Yanyan
|
|
2009
|
21-22 |
1-2 |
p. 17-27
11 p.
|
article
|
| 47 |
Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspective
|
Verheij, Marcel
|
|
2010
|
21-22 |
1-2 |
p. 29-43
15 p.
|
article
|
| 48 |
Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1
|
Gillet, Jean-Pierre
|
|
2012
|
21-22 |
1-2 |
p. 2-4
3 p.
|
article
|
| 49 |
Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics
|
Board, Ruth
|
|
2005
|
21-22 |
1-2 |
p. 75-83
9 p.
|
article
|
| 50 |
Resistance against novel anticancer metal compounds: Differences and similarities
|
Heffeter, Petra
|
|
|
21-22 |
1-2 |
p. 1-16
|
article
|
| 51 |
Resistance to antimalarial compounds: Methods and applications
|
Witkowski, Benoit
|
|
2009
|
21-22 |
1-2 |
p. 42-50
9 p.
|
article
|
| 52 |
Restoring p53-mediated apoptosis in cancer cells: New opportunities for cancer therapy
|
Yu, Qiang
|
|
2006
|
21-22 |
1-2 |
p. 19-25
7 p.
|
article
|
| 53 |
Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent
|
Katsman, Alina
|
|
2007
|
21-22 |
1-2 |
p. 1-12
12 p.
|
article
|
| 54 |
Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's Lymphoma
|
Bonavida, Benjamin
|
|
2005
|
21-22 |
1-2 |
p. 27-41
15 p.
|
article
|
| 55 |
Role of early plasma membrane events in chemotherapy-induced cell death
|
Dimanche-Boitrel, Marie-Thérèse
|
|
2005
|
21-22 |
1-2 |
p. 5-14
10 p.
|
article
|
| 56 |
Seminal contributions to the role of transport in antibacterial drug resistance recognized in a recent award
|
Georgopapadakou, Nafsika
|
|
2005
|
21-22 |
1-2 |
p. 3-4
2 p.
|
article
|
| 57 |
Starvation, detoxification, and multidrug resistance in cancer therapy
|
Lee, Changhan
|
|
2012
|
21-22 |
1-2 |
p. 114-122
9 p.
|
article
|
| 58 |
Targeting MDR in breast and lung cancer: Discriminating its potential importance from the failure of drug resistance reversal studies
|
Amiri-Kordestani, Laleh
|
|
2012
|
21-22 |
1-2 |
p. 50-61
12 p.
|
article
|
| 59 |
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
|
LoPiccolo, Jaclyn
|
|
|
21-22 |
1-2 |
p. 32-50
|
article
|
| 60 |
The dynamics of drug resistance: A mathematical perspective
|
Lavi, Orit
|
|
2012
|
21-22 |
1-2 |
p. 90-97
8 p.
|
article
|
| 61 |
The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance
|
Hastings, Ian M.
|
|
2005
|
21-22 |
1-2 |
p. 43-50
8 p.
|
article
|
| 62 |
The long road to colorectal cancer therapy: Searching for the right signals
|
Hollande, Frédéric
|
|
2010
|
21-22 |
1-2 |
p. 44-56
13 p.
|
article
|
| 63 |
The role of asymptomatic P. falciparum parasitaemia in the evolution of antimalarial drug resistance in areas of seasonal transmission
|
Babiker, Hamza A.
|
|
2013
|
21-22 |
1-2 |
p. 1-9
9 p.
|
article
|
| 64 |
The role of KLF6 and its splice variants in cancer therapy
|
DiFeo, Analisa
|
|
2009
|
21-22 |
1-2 |
p. 1-7
7 p.
|
article
|
| 65 |
The tumor microenvironment is a dominant force in multidrug resistance
|
Correia, Ana Luísa
|
|
2012
|
21-22 |
1-2 |
p. 39-49
11 p.
|
article
|
| 66 |
TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them
|
Thorburn, Andrew
|
|
|
21-22 |
1-2 |
p. 17-24
|
article
|
| 67 |
TRAIL receptor targeting therapies for non-small cell lung cancer: Current status and perspectives
|
Stegehuis, J.H.
|
|
2010
|
21-22 |
1-2 |
p. 2-15
14 p.
|
article
|
| 68 |
Tumor-specific nuclear targeting: Promises for anti-cancer therapy?
|
Alvisi, Gualtiero
|
|
2006
|
21-22 |
1-2 |
p. 40-50
11 p.
|
article
|
| 69 |
Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters
|
Özvegy-Laczka, Csilla
|
|
2005
|
21-22 |
1-2 |
p. 15-26
12 p.
|
article
|
| 70 |
Tyrosine kinase inhibitors and gemcitabine: New treatment options in pancreatic cancer?
|
Kleespies, Axel
|
|
2006
|
21-22 |
1-2 |
p. 1-18
18 p.
|
article
|
| 71 |
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
|
Shukla, Suneet
|
|
2012
|
21-22 |
1-2 |
p. 70-80
11 p.
|
article
|
| 72 |
Understanding the functions of tumor stroma in resistance to ionizing radiation: Emerging targets for pharmacological modulation
|
Chargari, Cyrus
|
|
2013
|
21-22 |
1-2 |
p. 10-21
12 p.
|
article
|
Journal description